T1	Person 0 5	Adult
T2	Measurement 51 54	MDS
T3	Value 31 50	intermediate-1 risk
T4	Value 24 27;46 50	low risk
*	OR T3 T4
T5	Scope 24 50	low or intermediate-1 risk
R1	Has_scope Arg1:T2 Arg2:T5	
T6	Drug 83 111	hematopoietic growth factors
T7	Temporal 112 146	within 3 months prior to screening
T8	Reference_point 137 146	screening
R2	Has_index Arg1:T7 Arg2:T8	
R3	Has_temporal Arg1:T6 Arg2:T7	
T9	Condition 160 166	anemia
T10	Qualifier 148 159	Symptomatic
R4	Has_qualifier Arg1:T9 Arg2:T10	
T11	Measurement 168 178	hemoglobin
T12	Value 179 187	<10 g/dL
R5	Has_value Arg1:T11 Arg2:T12	
R6	AND Arg1:T9 Arg2:T11	
T13	Measurement 220 240	Serum erythropoietin
T14	Value 241 267	<500 milliunits/milliliter
T15	Temporal 276 333	within 14 days prior to the first dose of study treatment
R7	Has_value Arg1:T13 Arg2:T14	
R8	Has_temporal Arg1:T13 Arg2:T15	
T16	Procedure 346 372	red blood cell transfusion
T17	Negation 343 345	no
T18	Multiplier 389 397	<4 units
T19	Temporal 398 431	within 8 weeks prior to screening
R9	Has_multiplier Arg1:T16 Arg2:T18	
R10	Has_negation Arg1:T16 Arg2:T17	
R11	Has_temporal Arg1:T16 Arg2:T19	
T20	Condition 444 450	stable
T21	Temporal 451 501	for at least 1 month prior to entry into the study
R12	Has_temporal Arg1:T20 Arg2:T21	
T22	Reference_point 481 501	entry into the study
R13	Has_index Arg1:T21 Arg2:T22	
T23	Pregnancy_considerations 503 707	For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception
